---
schema_version: "secwatch.filing_event.v1"
accession: "0000728387-26-000003"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T12:13:08.637016+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics reports FY2025 net loss $103M; lead program shows durable responses; cash ~$309M post-offering

## Summary
- Net loss $103.1M ($1.40/sh) vs $79.3M ($1.23) in FY2024; R&D spend $84.2M (+102% YoY).
- Cash $145M at Dec 31, 2025; Feb 2026 equity offering net proceeds ~$164M; runway into late 2027.
- VMT-α-NET: 76% progression-free at ~13 weeks additional follow-up; 39% objective response rate in Cohort 2.
- Cohort 3 cleared for more patients; all Cohort 2 expected to have ≥48 weeks follow-up by mid-2026.
- $10M non-cash impairment for deprioritized preclinical asset; three clinical programs continue.

## SEC filing metadata
- accession: 0000728387-26-000003
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/0000728387-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/catx-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000728387-26-000003
- JSON: https://secwatch.observer/filing/0000728387-26-000003.json
- Plain text: https://secwatch.observer/filing/0000728387-26-000003.txt

## Key facts
- Earnings Releases
  Perspective Therapeutics, Inc. reported financial results for the year ended December 31, 2025.
  - Period: the year ended December 31, 2025
  - Result: reported results
  source text: On March 16, 2026, Perspective Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025 and providing recent business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/0000728387-26-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.